The Latest Breaking News from Biogen

2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

Barchart · Feb 24, 2025

Biogen Stock Is Mutating Into a Value Play

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

MarketBeat · Feb 20, 2025

Stocks Settle Mixed as Chip Stock Strength Lifts the Nasdaq

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed down -0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.50%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.12%. March E-mini S&P futures (ESH25 ) are down by -0.29%, and March E-mini Nasdaq...

Barchart · Feb 12, 2025

Assessing Biogen: Insights From 19 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months.

Benzinga · Dec 9, 2024

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

StockNews.com · Nov 29, 2024

European committee takes a second look at Alzheimer's drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

The Independent UK · Nov 14, 2024

Biogen's Q3 2024 Earnings: What to Expect

Biogen will release its third-quarter earnings this month, and analysts anticipate a double-digit profit dip.

Barchart · Oct 24, 2024

Is Biogen Stock Underperforming the Dow?

Biogen has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart · Sep 20, 2024

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

International Business Times · Sep 20, 2024

Is Wall Street Bullish or Bearish on Biogen Stock?

Despite Biogen’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

Barchart · Aug 20, 2024